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Abstract  
Objective: 
To review a series of noninvasive encapsulated follicular variant of papillary thyroid carcinomas 
(FVPTC) in an attempt to further define the role of cytopathology in the diagnosis of 
noninvasive follicular thyroid neoplasm with papillary-like nuclear features and invasive FVPTC. 
Methods: 
Surgical pathology cases diagnosed as FVPTC with correlating thyroid fine needle aspiration 
(FNA) were identified and divided into two FVPTC groups: noninvasive and invasive. Cytologic 
diagnoses were compared between them.  
Results: 
We identified 23 cases that met the criteria for noninvasive FVPTC, and 27 cases that were 
typical infiltrative FVPTC (16) or encapsulated FVPTC with either capsular and/or 
lymphovascular invasion (11). Of the noninvasive FVPTC cases, there were 4 benign, 14 
follicular lesions of undetermined significance (FLUS), 4 follicular neoplasms (FN), 1 suspicious 
(S), and no papillary thyroid carcinomas (PTC). In the invasive FVPTC group, there was no 
benign, 4 FLUS, 3 FN, 12 suspicious, and 8 PTC cases. 
Conclusions: 
There is a distinction on the cytologic diagnosis between noninvasive and invasive FVPTC. The 
invasive subtype was diagnosed by FNA as suspicious for PTC or PTC in nearly 75% of cases 
while only 1 case (4%) for the noninvasive subtype was diagnosed as suspicious for PTC 
(p<0.05).  
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Introduction 
Ultrasound-guided fine-needle aspiration biopsy (FNAB) is the recommended modality for the 
evaluation of suspicious thyroid nodules. Since the introduction of FNAB, the incidence of 
thyroid carcinoma has nearly tripled.(1) At the same time, however, disease mortality has 
remained constant.(1) This paradox is attributed to the fact that we are diagnosing many more 
nonfatal cases, of which most are minimally invasive and minimally malignant tumors.(2) The 
noninvasive encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) falls into this 
category and numerous studies have demonstrated that this variant is unique in both its clinical 
behavior as well as its molecular profile.(3-5) It is now well documented that invasion correlates 
with clinical outcome in encapsulated tumors and the noninvasive FVPTCs can be managed 
clinically as follicular adenomas.(6, 7) Therefore, the Endocrine Pathology Society Working 
group on encapsulated FVPTC has proposed that these lesions be re-categorized as noninvasive 
follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). 
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is nearly widely used when 
reporting thyroid cytopathology and each category has a known implied risk of malignancy and 
recommended clinical management.(8) As expected, reclassifying noninvasive FVPTC as NIFTP 
will have an impact on the rate of malignancy for each of TBSRTC categories. Faquin et al 
recently published data showing that this reclassification would have the most impact on the 3 
indeterminate categories of TBSRTC: the atypia of undermined significance/follicular lesion of 
undetermined significance (AUS/FLUS) category would have a decrease risk of malignancy of 
5.2% to 13.6%, the follicular neoplasm (FN) category would have a decrease risk of malignancy 
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of 9.9% to 15.1%, and the suspicious (S) category would have a decrease risk of malignancy of 
17.6% to 23.4%.(9) This data reiterates the findings of a previous study by Strickland et al which 
concluded that if the terminology were changed, the rates of malignancy for FNA diagnostic 
categories would be decreased.(10) 
This re-classification will theoretically help reduce the pressure felt by clinicians to treat 
“borderline” cancers and cytopathologists alike could practice with “reduced concern for 
minimal cytologic findings that lead to the overuse of the AUS/FLUS category.”(11) As such, we 
have reviewed a series of FVPTCs in an attempt to further define the role of cytopathology in 
the diagnosis of NIFTP and invasive FVPTC. 
Materials and Methods 
This study was approved by the Indiana University Institutional Review Board. A computerized 
search of our pathology laboratory information system was performed to identify all surgical 
pathology diagnosed as FVPTC with correlating thyroid FNAB at our institution for the 5-year 
period from 2010 through 2014. FNAB cases were categorized using TBSRTC. 
Patient data were collected and included the age and sex, the size and location of the sampled 
nodule, and the surgical follow-up. Only cases where the resected nodule correlated with the 
nodule sampled by FNAB were included in our study. 
The cytologic and surgical pathology reports as well as pertinent clinical history and 
radiographic results were reviewed. The air-dried (modified Wright-Giemsa stained) and 
ethanol fixed (Papanicolaou-stained) direct smears from the thyroid aspirates and the histologic 
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slides of the corresponding surgical resections were reexamined independently by both 
authors. The authors were blinded to the surgical pathology diagnoses at the time of the 
review. Both authors then sat at a double microscope to resolve any discrepancy. Based on the 
histology from the surgical resection specimens, cases were divided into two groups: cases that 
meet the criteria for NIFTP (noninvasive FVPTC) and invasive FVPTC. The noninvasive group was 
defined by tumors with papillary thyroid carcinoma-like nuclear aberrations (as opposed to 
follicular adenomas which lack this nuclear atypia) with a well-defined growth pattern with a 
total or partial fibrous capsule and were negative for capsular and/or lymphovascular invasion 
or extrathyroidal extension.  Invasive FVPTC cases included an infiltrative type of FVPTC 
(unencapsulated tumors with infiltrative features and conventional papillary nuclear features) 
and an encapsulated FVPTC with capsular and/or lymphovascular invasion. Cytologic diagnoses 
were compared between the two groups. Statistical analysis using the chi-square test was 
performed through a web calculator 
(http://www.socscistatistics.com/tests/chisquare/Default.aspx). Statistical significance is set at 
5% (P<0.05). 
Results 
A total of 287 surgical pathology cases were identified, of which 50 had correlating FNA 
samples. All FNAB cases were adequate for evaluation. Of the 50 cases, 23 cases met the 
criteria for noninvasive FVPTC, 16 cases were typical infiltrative FVPTC and the remaining 11 
cases were encapsulated FVPTC with either capsular and/or lymphovascular invasion. Only two 
of 16 cases of infiltrative FVPTC showed coexisting angiovascular invasion.  
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In the noninvasive FVPTC group, ages ranged from 30-81 and the male to female ratio was 3:20. 
Tumor sized ranged from 0.4-5.1 cm with a median size of 1 cm and an average size of 1.3 cm 
(n=27).  In the invasive FVPTC group, ages ranged from 25-69 and the male to female ration was 
6:21. Tumor sized ranged from 0.3-7.2 cm with a median size of 1.6 cm and an average size of 2 
cm (n=23).  Of the noninvasive FVPTC cases, 4 (17%) were diagnosed as benign (B), 14 (61%) 
were diagnosed as follicular lesion of undetermined significance (FLUS), 4 (17%) were 
diagnosed as follicular neoplasm (FN), 1 (4%) were diagnosed as suspicious (S), and none were 
diagnosed as papillary thyroid carcinoma (PTC). In the invasive FVPTC group, none was 
diagnosed as B, 4 (15%) cases were diagnosed as FLUS, 3 (11%) cases were diagnosed as FN, 12 
(44%) cases were diagnosed as suspicious, and 8 (30%) cases were diagnosed as PTC (Table 1).  
The invasive subtype was diagnosed by FNAB as suspicious for PTC or PTC in nearly 75% of 
cases while only 1 case (4%) for the noninvasive subtype was diagnosed as suspicious for PTC 
(p<0.05).  61% of cases diagnosed as FLUS turned out to be noninvasive while only 15% were 
invasive (p<0.05). 
Discussion 
FVPTC represents a large portion of PTC cases and appears to be increasing in incidence. (9, 12-
14) Noninvasive FVPTC comprises a significant portion of the FVPTC diagnoses.(9, 13, 14) The 
importance of recognizing the distinction between the invasive and noninvasive counterpart 
has become clearer over the past decade since we now know that the noninvasive FVPTC 
behaves in a distinctly indolent manner and can be treated as a follicular adenoma.(6, 7) While 
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the distinction between these two counterparts is easily recognized on the histologic level, the 
differences between the two on the cytologic level is often undervalued. 
At our institution, noninvasive FVPTC was most often categorized as FLUS by FNAB, 
representing 61% of the cases. The second most common FNAB diagnosis was benign (17%). In 
contrast, invasive FVPTC was diagnosed as suspicious for PTC in 44% of cases and as outright 
PTC in 30% of cases. Moreover, none of the cases of noninvasive FVPTC were diagnosed as PTC 
and none of the cases of invasive FVPTC were diagnosed as benign. 
Our data suggest that there is a cytomorphologic distinction between noninvasive FVPTC and 
invasive FVPTC. The invasive subtype, encompassed both infiltrative and encapsulated FVPTC 
with either capsular or angiovascular invasion, was diagnosed by FNAB as suspicious for PTC or 
PTC in nearly 75% of cases while only 1 case (4%) for the noninvasive subtype was diagnosed as 
suspicious for PTC. It is our impression that the invasive variant showed more obvious 
diagnostic nuclear aberrations (Figure 1). The invasive variant also tends to have higher 
cellularity of atypical cells with easily identifiable nuclear irregularity, grooves, and 
pseudoinclusions, leads to a more definite cytologic diagnosis (suspicious for PTC or PTC). Cases 
of noninvasive FVPTC displayed only subtle nuclear changes and were overall less cellular. A 
more thorough, high-power examination was required to spot the nuclear aberrations.  The 
nuclear aberrations often included subtle nuclear grooves or minor nuclear enlargement.  
Nuclear pseudoinclusions were not easily identified. The nuclei of non-invasive variant tend to 
be more rounded and less irregular than the invasive type (Figure 2).  It is our impression that 
while individual cytologic features cannot be used as a predictor of invasion, the overall 
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cellularity and ease of identifying the atypia in the individual cases (leading to diagnoses of FLUS 
versus suspicious) is important. Cases diagnosed as FLUS were much more likely to fall into the 
noninvasive camp, 61% versus 15% of the invasive variant. The proportion of cases diagnosed 
as FN was similar in both groups (3 cases for invasive vs. 4 cases form non-invasive type).  
Overall we note a clear difference in FNA diagnoses between noninvasive FVPTC and invasive 
FVPTC.  We found that the median size of those lesions that turn out to be noninvasive is 1 cm 
compared to 1.6 cm in those that fell into the invasive camp.  This size difference could account 
for higher cellularity due to more accurate sampling in the larger lesions and allowing for a 
more definitive diagnosis. 
 
Additionally, at our institution, we use fairly strict criteria for a suspicious diagnosis. Our risk of 
malignancy for suspicious is 93% (5-year review of 2531 cases, unpublished data, including 
papillary microcarcinoma) and will be 90% if excluding NIFTP.  Cases that reveal only focal or 
less convincing cytologic features of papillary carcinoma are classified as FLUS or FLUS cannot 
exclude papillary carcinoma (risk of malignancy  is 36% for FLUS including papillary 
microcarcinoma and 27% if excluding NIFTP).  This could account for the discrepancy we saw in 
our data compared to other published data. 
 
Our data shows that at our institution FNA is clearly an effective method to identify invasive 
FVPTC. An FNA diagnosis of suspicious for PTC or PTC has a high likelihood of being an invasive 
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FVPTC. An FNA diagnosis of FLUS is encountered much more often in noninvasive FVPTC and, 
thus, a more conservative clinical management approach should be favored. Ancillary 
molecular testing for BRAF and RAS might be warranted in this setting. 
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Figure legends 
Figure 1. FNA cytology of invasive FVPTC demonstrating characteristic cytologic feature of 
papillary carcinoma. (A) Tumor cells show oval nuclei with nuclear enlargement, overlapping, 
irregular nuclear membrane, intranuclear pseudoinclusion (Papanicolaou staining, x400), (B) 
frequent nuclear grooves (Papanicolaou staining, x400), and (C) dense colloid in the background 
(Diff-Quik staining, x400). 
Figure 2. FNA cytology of noninvasive FVPTC. (A) Nuclei are mildly enlarged, with less 
membranous irregularity and nuclear overlapping (Diff-Quik staining x400). (B) Nuclear grooves 
are not as frequent (Papanicolaou staining, x 400). 
